SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)


  • Org Study ID: XmAb22841-01
  • Secondary ID: DUET-4
  • NCT ID: NCT03849469
  • NCT Alias:
  • Sponsor: Xencor, Inc. - Industry
  • Source: Xencor, Inc.

Brief Summary

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

Overal Status Start Date Phase Study Type
Recruiting May 29, 2019 Phase 1 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.

Primary Outcome 1 - Time Frame: 56 Days

Condition:

  • Melanoma
  • Cervical Carcinoma
  • Pancreatic Carcinoma
  • Triple Negative Breast Cancer
  • Hepatocellular Carcinoma
  • Urothelial Carcinoma
  • Squamous Cell Carcinoma of the Head and Neck
  • Nasopharyngeal Carcinoma
  • Renal Cell Carcinoma
  • Colorectal Carcinoma
  • Endometrial Carcinoma
  • Non-small Cell Lung Carcinoma
  • Small Cell Lung Carcinoma
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • Advanced or Metastatic Solid Tumors
  • Prostate Carcinoma
  • MSI-H
  • Mismatch Repair Deficiency

Eligibility

Criteria:
Inclusion Criteria:

1. All subjects' cancer must have progressed after treatment with all available therapies
that are known to confer clinical benefit, or are intolerant to treatment, or refuse
standard treatment.

2. All subjects must have adequate archival tumor, or give consent to a fresh tumor
biopsy.

3. Subjects have an ECOG performance status of 0-1.

4. Subjects in monotherapy and combination therapy cohorts must have histologically or
cytologically confirmed advanced or metastatic solid tumors, including the following:

1. Melanoma (excluding uveal melanoma)

2. Cervical carcinoma

3. Pancreatic carcinoma

4. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2
negative (TNBC)

5. Hepatocellular carcinoma

6. Urothelial carcinoma

7. Squamous cell carcinoma of the head and neck (HNSCC)

8. Nasopharyngeal carcinoma (NPC)

9. Renal cell carcinoma

10. Microsatellite instability-high or mismatch repair deficient tumors

11. Small cell lung carcinoma or NSCLC

12. Gastric or gastroesophageal junction adenocarcinoma

13. Prostate adenocarcinoma

14. Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab
must have histologically or cytologically confirmed advanced solid tumors for
which pembrolizumab is an approved indication and that has not previously been
treated with an agent targeting PD1 or PDL1.

Exclusion Criteria:

1. Prior treatment with an investigational anti-LAG3 therapy.

2. Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for
Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, and 4P; and
within 3 weeks for Cohorts 6M, 7M, 5P, and 6P.

3. Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the
first dose of study treatment; or radiotherapy within 2 weeks of the first dose of
study treatment; or small molecule kinase inhibitors within 6 elimination half-lives
of the first dose of study treatment.

4. Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an
agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX
40, CD137) AND were permanently discontinued from that treatment due to an IRAE.

5. Failure to recover from any IRAE from prior cancer therapy to Grade ≤ 1.

6. Failure to recover from any other toxicity (other than immune-related toxicity)
related to previous anticancer treatment to Grade ≤ 2.

7. Active known or suspected autoimmune disease (except that subjects are permitted to
enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to
an autoimmune condition that is treatable with hormone replacement therapy only;
psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed
without systemic therapy; or arthritis that is managed without systemic therapy beyond
oral acetaminophen and non-steroidal anti-inflammatory drugs).

8. Receipt of an organ allograft.

9. Treatment with antibiotics within 14 days prior to first dose of study drug.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Wayne Saville, MD

Role: Study Director

Affiliation: Xencor, Inc.

Overall Contact

Name: Wayne Saville, MD

Phone: 858-480-3410

Email: wsaville@xencor.com

Locations

Facility Status Contact
Emory University
Atlanta, Georgia 30322
United States
Recruiting
Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Recruiting
Mary Crowley Cancer Research - Medical City
Dallas, Texas 75230
United States
Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas 77030
United States
Recruiting